» Articles » PMID: 20535799

Atherosclerotic Vascular Events in a Multinational Inception Cohort of Systemic Lupus Erythematosus

Abstract

Objective: To describe vascular events during an 8-year followup in a multicenter systemic lupus erythematosus (SLE) inception cohort and their attribution to atherosclerosis.

Methods: Clinical data, including comorbidities, were recorded yearly. Vascular events were recorded and attributed to atherosclerosis or not. All of the events met standard clinical criteria. Factors associated with atherosclerotic vascular events were analyzed using descriptive statistics, t-tests, and chi-square tests. Stepwise multivariate logistic regression was used to assess the association of factors with vascular events attributed to atherosclerosis.

Results: Since 2000, 1,249 patients have been entered into the cohort. There have been 97 vascular events in 72 patients, including: myocardial infarction (n = 13), angina (n = 15), congestive heart failure (n = 24), peripheral vascular disease (n = 8), transient ischemic attack (n = 13), stroke (n = 23), and pacemaker insertion (n = 1). Fifty of the events were attributed to active lupus, 31 events in 22 patients were attributed to atherosclerosis, and 16 events were attributed to other causes. The mean +/- SD time from diagnosis to the first atherosclerotic event was 2.0 +/- 1.5 years. Compared with patients followed for 2 years without atherosclerotic events (n = 615), at enrollment, patients with atherosclerotic vascular events were more frequently white, men, older at diagnosis of SLE, obese, smokers, hypertensive, and had a family history of coronary artery disease. On multivariate analysis, only male sex and older age at diagnosis were associated factors.

Conclusion: In an inception cohort with SLE followed for up to 8 years, there were 97 vascular events, but only 31 were attributable to atherosclerosis. Patients with atherosclerotic events were more likely to be men and to be older at diagnosis of SLE.

Citing Articles

Future atherosclerotic cardiovascular disease in systemic lupus erythematosus based on CSTAR (XXVIII): the effect of different antiphospholipid antibodies isotypes.

Huang C, Ding Y, Chen Z, Wu L, Wei W, Zhao C BMC Med. 2025; 23(1):8.

PMID: 39757171 PMC: 11702278. DOI: 10.1186/s12916-024-03843-9.


Deciphering Mechanisms, Prevention Strategies, Management Plans, Medications, and Research Techniques for Strokes in Systemic Lupus Erythematosus.

Al-Ewaidat O, Naffaa M Medicines (Basel). 2024; 11(7).

PMID: 39189161 PMC: 11348055. DOI: 10.3390/medicines11070015.


Personalizing cardiovascular risk prediction for patients with systemic lupus erythematosus.

Choi M, Guan H, Yoshida K, Paudel M, Kargere B, Li D Semin Arthritis Rheum. 2024; 67:152468.

PMID: 38788567 PMC: 11214838. DOI: 10.1016/j.semarthrit.2024.152468.


rs9514828 C>T Polymorphism is Associated with Incidence of Atherosclerosis and Therapeutic Outcomes in Patients with Systemic Lupus Erythematosus.

Fajar D, Rostinawati T, Hamijoyo L, Sahiratmadja E, Amalia R, Barliana M Biologics. 2024; 18:95-106.

PMID: 38715569 PMC: 11075687. DOI: 10.2147/BTT.S452792.


Cardiovascular risk factors and complications in patients with systemic lupus erythematosus with and without nephritis: a systematic review and meta-analysis.

Wong C, Ma B, Zhang D, Cheung W, Chan T, Yap D Lupus Sci Med. 2024; 11(1).

PMID: 38519060 PMC: 10961538. DOI: 10.1136/lupus-2024-001152.


References
1.
Nikpour M, Urowitz M, Gladman D . Premature atherosclerosis in systemic lupus erythematosus. Rheum Dis Clin North Am. 2005; 31(2):329-54, vii-viii. DOI: 10.1016/j.rdc.2005.01.001. View

2.
Toloza S, Uribe A, McGwin Jr G, Alarcon G, Fessler B, Bastian H . Systemic lupus erythematosus in a multiethnic US cohort (LUMINA). XXIII. Baseline predictors of vascular events. Arthritis Rheum. 2004; 50(12):3947-57. DOI: 10.1002/art.20622. View

3.
Tunstall-Pedoe H, Kuulasmaa K, Amouyel P, Arveiler D, Rajakangas A, Pajak A . Myocardial infarction and coronary deaths in the World Health Organization MONICA Project. Registration procedures, event rates, and case-fatality rates in 38 populations from 21 countries in four continents. Circulation. 1994; 90(1):583-612. DOI: 10.1161/01.cir.90.1.583. View

4.
Gladman D, Urowitz M, Goldsmith C, Fortin P, Ginzler E, Gordon C . The reliability of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index in patients with systemic lupus erythematosus. Arthritis Rheum. 1997; 40(5):809-13. DOI: 10.1002/art.1780400506. View

5.
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M . The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996; 39(3):363-9. DOI: 10.1002/art.1780390303. View